See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Amazon
Social Media
Floods
Natural Disasters
Donald Trump
Justice
Education
Artificial Intelligence
Crime
Music
Heatwaves
Immigration and Customs Enforcement
DirectorsTalk Interviews image

News from DirectorsTalk Interviews

If you want to know if DirectorsTalk Interviews is credible or reliable, look no further. We rank DirectorsTalk Interviews as Unknown factuality. Find out more about our methodology here.

Information about DirectorsTalk Interviews

Where is DirectorsTalk Interviews located?DirectorsTalk Interviews's Website

Media Bias Ratings

Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.

Factuality

Learn more about  Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about  Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top DirectorsTalk Interviews News

Trump announces 50% tariff on copper effective August 1
Tariffs · United States

Trump announces 50% tariff on copper effective August 1

41% Center coverage: 112 sources
U.S. President Donald Trump announced on Wednesday a 50% tariff on copper, saying on social media that it would be effective August 1 and that the decision was made after a national security assessment.See the Story
China's consumer prices rise for first time in five months
China Economy · China

China's consumer prices rise for first time in five months

50% Center coverage: 38 sources
China's consumer prices rose for the first time in five months in June while producer deflation worsened, as the economy grapples with uncertainty over a global trade war and subdued demand at home. See the Story
The Stock Market No Longer Fears Tariffs
Warren Buffett

The Stock Market No Longer Fears Tariffs

50% Center coverage: 10 sources
Stocks, bitcoin, and Nvidia are setting records even as Trump announces new tariffs.See the Story

WPP Plunges 16%, Leads FTSE 100 Lower On Profit Warning

90% Center coverage: 10 sources
Like-for-like revenues (excluding pass through costs) are expected to drop between 3% and 5%, the FTSE 100 advertising giant said.Business · LondonSee the Story

Gold ETFs Drew Largest Inflow in Five Years During First Half of 2025 ...

67% Center coverage: 3 sources
Physically backed gold ETFs attracted the biggest semi-annual increase in flows since early 2020,MiningSee the Story

A New Current Steering Britain’s Industry

A subtle shift is underway at the heart of the UK’s industrial ambitions, ushered in by a company few had on their radar until now. The stakes are high: decarbonisation targets loom, supply chains strain under geopolitical tensions and energy security has vaulted to the top of every boardroom agenda. Within this charged atmosphere, Ilika occupies a peculiar vantage point, quietly converting material science breakthroughs into potentially transfo…United Kingdom · United KingdomRead Article

Unearthing Hidden Potential In European Smaller Companies

A quiet shift in stewardship is coinciding with seismic policy changes across the continent, creating a landscape where lesser-known businesses may finally step into the limelight. As Berlin ramps up infrastructure spending and Brussels commits fresh funds to defence, a carefully rebalanced portfolio of nimble mid-tier firms stands poised to capture the momentum, even if wider markets are only just waking to the opportunity. When a new team took…Read Article

Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference

100% Right coverage: 1 sources
CELEBRATION, Fla., July 11, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced an oral presentation and two poster presentations on MIPLYFFA® (MY-PLY-FAH) (arimoclomol) are being featured at the National Niemann Pick Disease Foundation (NNPDF) Conference, taking place July 10-13, 2025, in Concord…Concord, North Carolina · ConcordSee the Story

Hydrogen And Helium Signals Below South Australia

An elusive whisper from beneath the earth’s surface has captivated the attention of resource investors, suggesting that southern Australia may harbour more than just minerals in its hidden depths. Beneath the arid expanse of the Hy Range project, a network of anomalies has emerged that paints a picture of a dynamic and densely charged gas system, one that could redefine how explorers and energy strategists view the Outback. Early soil gas traver…South Australia · South AustraliaRead Article

Standard BioTools Inc. (LAB) Stock Analysis: Exploring A Potential 75.93% Upside

Standard BioTools Inc. (NASDAQ: LAB), a key player in the healthcare sector’s medical devices industry, has been catching the eye of investors due to its promising potential upside. With a current market capitalization of $487.68 million and a stock price of $1.35, the company presents an intriguing opportunity, particularly as analysts have set an average target price of $2.38, indicating a potential upside of 75.93%. Founded in 1999 and headqu…South San Francisco · South San FranciscoRead Article

Rapport Therapeutics, Inc. (RAPP) Stock Analysis: A Deep Dive Into Its 127.57% Potential Upside

Rapport Therapeutics, Inc. (RAPP) is making waves in the biotech sector with a promising lineup of innovative solutions targeting central nervous system (CNS) disorders. Operating as a clinical-stage biopharmaceutical company, Rapport focuses on the discovery and development of transformational small molecule medicines. Its strategic focus on CNS disorders positions it uniquely within the healthcare landscape, drawing significant interest from i…Read Article

Breaking News Topics Related to DirectorsTalk Interviews

Israel-Hamas Conflict icon

Israel-Hamas Conflict

News
For You
SearchBlindspotLocal